[TNFalpha inhibitors for the treatment of rheumatoid arthritis].
Reasons for using TNFalpha inhibitors in rheumatoid arthritis Available agents modulating TNFalpha Adverse effects to TNFalpha inhibitors Which patients should be treated with TNFalpha inhibitors? Monitoring treatment with TNFalpha inhibitors Patient follow-up Open questions Conclusions
Sany
Jacques
J
Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, CHU, 371, avenue du Doyen-Gaston-Giraud, 34295 Montpellier Cedex 5, France. j-sany@chu-montpellier.fr
Kaiser
Marie-Joëlle
MJ
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001986:Bronchial Spasm / Q000209:etiology; D000068800:Etanercept; D006261:Headache / Q000209:etiology; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014581:Urticaria / Q000209:etiology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept